At oral doses of 25 mg/kg daily, RMC-6236 showed encouraging activity and durable responses in murine studies with KRAS G12X lung cancer, pancreatic cancer and colorectal cancer xenografts. This evidence concerns the gene KRAS and familial pancreatic carcinoma.